se of Olaparib, a drug that inhibits an enzyme linked to inflammatory response and DNA repair, in sepsis

Phase 2

• Conditions: septic shock; C01.757

• Registration Number: RBR-8xdc8yz
• Lead Sponsor: Escola Paulista de Medicina, Universidade Federal de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-12-30
• Last Update Posted: 29 May 2023
• Study Completion: 2024-12-15

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

Male patients diagnosed with septic shock for less than 24 hours; signing of free and informed consent form

Exclusion Criteria

Female patients (women) because women's hormones can alter the effects of olaparib; patients unable to use medication by mouth or by tube; patients with AIDS; patients using immunosuppressive therapy, that is, which compromises the body's defenses; patients using corticosteroids; patients with cancer or undergoing chemotherapy; chemotherapy performed up to 30 days; patients who had cardiac arrest; patients with recent acute infarction or problems with the coronary artery, the artery that supplies the heart; liver disease, such as liver cirrhosis; very severe patients, with the prospect of death within 24 hours; palliative or end-of-life care; patients using treatments that may have their effects altered or alter the effects of olaparib (examples: itraconazole, fluconazole, verapamil, rifampicin, phenytoin, carbamazepine, phenobarbital and modafinil; Saint John's herb)

Study & Design

• Study Type: Intervention
• Study Design: Not specified